New drug trial offers hope for advanced breast cancer patients who ran out of options
NCT ID NCT06081959
Summary
This study is testing whether an experimental drug called SKB264 works better than standard chemotherapy for people with advanced HR+/HER2- breast cancer that has spread or returned after at least one round of prior chemotherapy. About 376 participants will be randomly assigned to receive either SKB264 or a treatment chosen by their doctor. The main goal is to see if SKB264 can help patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
Conditions
Explore the condition pages connected to this study.